Skip to main content
. 2021 Oct;192:114697. doi: 10.1016/j.bcp.2021.114697

Fig. 6.

Fig. 6

Targeting active TGF-β1 production by Tregs. a Tregs produce active TGF-β1 via GARP and integrin αVβ8. Active TGF-β1 can suppress effector T cells and could contribute to tumor escape. b An anti-GARP:TGF-β1 monoclonal antibody blocks active TGF-β1 production by Tregs. Our hypothesis is that consequently, CTLs would not receive TGF-β1 inhibitory signals and could be more efficient to eliminate tumor cells.